Targeted Protein Degradation Market Size is valued at USD 0.42 Bn in 2023 and is predicted to reach USD 2.65 Bn by the year 2031 at an 26.3% CAGR during the forecast period for 2024-2031.
Targeted Protein Degradation (TPD) is a novel therapeutic strategy that harnesses the cell's natural protein disposal system to eliminate unwanted proteins. Instead of inhibiting a protein's activity, TPD molecules tag the protein for destruction by the proteasome, a cellular machine responsible for breaking down proteins. Targeted protein degradation (TPD) is a cutting-edge drug discovery strategy that eliminates problematic proteins from cells by leveraging cellular degradation processes using small molecules. One such process is the ubiquitin-proteasome pathway, a quality control mechanism that tags damaged or misfolded proteins for destruction by the proteasome.
The field of TPD is witnessing continuous advancements in areas like degrader design, leading to more potent and selective molecules with the ability to target a wider range of proteins. Additionally, research is ongoing to overcome challenges like off-target effects and delivery methods, further strengthening the market's potential. Encouraging results from ongoing clinical trials involving TPD therapies boost investor confidence and accelerate market growth. As more drugs successfully navigate clinical trials and reach patients, the market is poised for significant expansion.
Competitive Landscape
Some of the Major Key Players in the Targeted Protein Degradation Market are
- Arvinas
- Bristol-Myers Squibb
- C4 Therapeutics
- Loxo Oncology
- Olema Oncology
- Radius Health
- AstraZeneca
- Roche
- BeiGene
- InnoCare Pharma
- Kangpu Biopharmaceuticals
- Kintor Pharmaceuticals
- Medivir
- Monte Rosa Therapeutics
- Ranok Therapeutics
- Sanofi
- Zentalis Pharmaceuticals
- Eisai Therapeutics
Market Segmentation:
The PROTAC segment is Expected to have the highest growth rate during the forecast period
Based on the distribution by type of degrader categorized into SERD, PROTAC and molecular glue. Among these, the PROTAC segment is expected to have the highest growth rate during the forecast period. PROTACs cleverly leverage the cell's existing protein disposal system, the ubiquitin-proteasome pathway. This inherent cellular mechanism provides a powerful and efficient method to degrade target proteins, making PROTACs a highly attractive therapeutic approach. Ongoing research and clinical trials involving PROTACs are yielding encouraging results, which in turn fuels investor confidence and accelerates the development of PROTAC-based therapies. This growing scenario is propelling the market forward, highlighting the potential of PROTACs to transform the landscape of disease treatment.
The Breast Cancer Segment Dominate the Market
Target indications are categorized as breast cancer and multiple myeloma. The breast cancer segment dominates the market. Breast cancer research has provided fertile ground for the targeted protein degradation (TPD) market. The identification of key protein targets involved in breast cancer growth, like hormone receptors and cell proliferation proteins, makes them prime candidates for TPD strategies using PROTACs. Early success in clinical trials with these PROTACs has fueled significant investor interest and further research, solidifying breast cancer as the leading player in the TPD market. TPD therapies using PROTACs have the potential to work synergistically with existing breast cancer treatments like chemotherapy and targeted therapies. This opens doors for developing combination regimens with potentially improved efficacy and outcomes.
North America Led the Targeted Protein Degradation Market
North America faces significant limitations of chronic diseases like cancer and neurodegenerative diseases, which are potential targets for TPD therapies. The high prevalence of these diseases creates a strong demand for novel treatment options, driving market growth. North American countries are generally more receptive to adopting new and innovative healthcare technologies. This openness allows for faster clinical trial approvals and earlier access to promising TPD therapies for patients.
Recent Developments:
- In April 2024, Arvinas, Inc., announced that it has signed an exclusive strategic license agreement with Novartis for the global development and commercialization of ARV-766, Arvinas' second-generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. is a clinical-stage biotechnology company developing a new class of drugs based on targeted protein degradation. An asset purchase agreement for the sale of Arvinas' preclinical AR-V7 program to Novartis is also a part of the transaction.
- In September, 2023, Bristol Myers Squibb is hosting a Research and Development (R&D) Day in New York to discuss the company's R&D capabilities and strategy to provide information about its strong pipeline that supports sustainable long-term growth. The company's leadership team will also showcase its improved R&D framework and unique research platforms, which are anticipated to provide exceptional productivity that produces top-notch early-stage candidates and noticeably shortens R&D timelines.
Targeted Protein Degradation Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 0.42 Bn |
|
Revenue Forecast In 2031 |
USD 2.65 Bn |
|
Growth Rate CAGR |
CAGR of 26.3% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Distribution by Type of Degrader, Target Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Arvinas, Bristol-Myers Squibb, C4 Therapeutics,Loxo Oncology, Olema Oncology, Radius Health,AstraZeneca, Roche, BeiGene, InnoCare Pharma,Kangpu Biopharmaceuticals, Kintor Pharmaceuticals, Medivir, Monte Rosa Therapeutics, Ranok Therapeutics, Sanofi, Zentalis Pharmaceuticals, Eisai Therapeutics |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
